S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%
Incyte

INCY Q1 2026 Earnings

Reported Apr 28, 2026 at 7:03 AM ET · SEC Source

Q1 26 EPS

$1.81

Q1 26 Revenue

$1.27B

BEAT +4.65%

Est. $1.22B

vs S&P Since Q1 26

-0.8%

TRAILING MARKET

INCY +0.5% vs S&P +1.3%

Market Reaction

Did INCY Beat Earnings? Q1 2026 Results

Incyte Corporation posted a blowout first quarter for 2026, with earnings per share of $1.81 beating the $1.34 consensus estimate by 35.13% and revenue of $1.27 billion topping expectations by 4.65% while climbing 20.9% year over year. The standout d… Read more Incyte Corporation posted a blowout first quarter for 2026, with earnings per share of $1.81 beating the $1.34 consensus estimate by 35.13% and revenue of $1.27 billion topping expectations by 4.65% while climbing 20.9% year over year. The standout driver was broad-based commercial momentum across the portfolio, headlined by Jakafi's 7% growth to $757.75 million and a surging hematology and oncology segment that rose 116% to $204 million, fueled by rapid uptake of newer launches including Zynyz and Niktimvo. Operating leverage was on full display as well, with GAAP operating income rising 47% to $301.12 million even as R&D investment climbed 18% to $515.90 million to support 10 active Phase 3 programs. With institutional ownership approaching 97%, investor confidence in the pipeline appears well-anchored. Incyte reaffirmed its full-year 2026 guidance for total net sales of $4.77 to $4.94 billion and is positioning for four product approvals and launches stretching from mid-2026 into early 2027, including povorcitinib in hidradenitis suppurativa and the anticipated Jakafi XR rollout.

Key Takeaways

  • • Jakafi net sales grew 7% driven by 6% increase in paid demand across all indications
  • • Opzelura net sales grew 20% driven by increased patient demand in atopic dermatitis and vitiligo
  • • Hematology and Oncology portfolio net sales grew 116% driven by Niktimvo, Monjuvi/Minjuvi, and Zynyz in SCAC
  • • Niktimvo net sales grew 305% year-over-year
  • • Zynyz net sales grew 1,276% year-over-year following first-line SCAC launch
  • • Product royalty revenues grew 16% to $151 million
  • • $17 million in milestone and contract revenues earned in Q1 2026
  • • SG&A expenses grew only 1% year-over-year, demonstrating operating leverage

INCY Forward Guidance & Outlook

Incyte reaffirmed its full-year 2026 financial guidance across all categories: total net sales of $4,770–$4,940 million, Jakafi net sales of $3,220–$3,270 million (including initial Jakafi XR launch), Opzelura net sales of $750–$790 million (including anticipated EU approval for moderate atopic dermatitis in H2 2026), and Hematology and Oncology net sales of $800–$880 million. Total GAAP R&D and SG&A operating expenses are expected to be $3,495–$3,675 million, and Non-GAAP R&D and SG&A of $3,205–$3,375 million. The company anticipates four product approvals and launches from mid-2026 into early 2027, including Jakafi XR (U.S. mid-2026), Opzelura in moderate AD (EU H2 2026), and povorcitinib in HS (EU late 2026, U.S. Q1 2027).

24/7 Wall St

INCY YoY Financials

Q1 2026 vs Q1 2025, source: SEC Filings

24/7 Wall St

INCY Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 25 Q1 26

“Our first quarter represented a strong start to 2026, driven by 20% year-over-year net sales growth and strong commercial execution. At the same time, we are making significant progress toward building a more durable, growth oriented portfolio with four anticipated product approvals and launches over the next 12 months, positive registrational data for povorcitinib in vitiligo and a late stage pipeline that now includes 10 Phase 3 studies underway, including the initiation of a pivotal trial of our G12D inhibitor in first line pancreatic ductal adenocarcinoma.”

— Bill Meury, Q1 2026 Earnings Press Release

Back to INCY Stock Page